Search - tctmd.com

Displaying 21 - 40 of 101

Sort: Relevancy | Date

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

News Conference News ACC 2023

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

March 10, 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low Risk Patients: 3-Year Outcomes from the EvolutLow Risk Trial

Presentation ACC 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Presenter: John K. Forrest

March 05, 2023

A Landmark Randomized Clinical Trial of Transcatheter Repair for Tricuspid Regurgitation

Presentation ACC 2023

A Landmark Randomized Clinical Trial of Transcatheter Repair for Tricuspid Regurgitation

Presenter: Paul Sorajja

March 05, 2023

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Presentation ACC 2023

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Presenter: Gregg W. Stone

March 05, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

News Conference News ACC 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

March 04, 2023

Mountains of Cath Lab Waste Could Be Recycled, Study Estimates

News Conference News ACC 2023

Mountains of Cath Lab Waste Could Be Recycled, Study Estimates

March 01, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.